100 related articles for article (PubMed ID: 8579069)
21. Thymidine kinase in neoplastic haematological diseases: confirmations, doubts and new findings.
Musto P; Longo S; Morelli A; Ficola U; Falcone A; Carotenuto M
Haematologica; 1988; 73(6):545-6. PubMed ID: 3148519
[No Abstract] [Full Text] [Related]
22. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
23. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients.
Zhang J; Jia Q; Zou S; Zhang P; Zhang X; Skog S; Luo P; Zhang W; He Q
Oncol Rep; 2006 Feb; 15(2):455-61. PubMed ID: 16391869
[TBL] [Abstract][Full Text] [Related]
24. Significance of serum ferritin and lactate dehydrogenase in benign and malignant disease of breast.
Kher A; Moghe G; Deshpande A
Indian J Pathol Microbiol; 1997 Jul; 40(3):321-6. PubMed ID: 9354001
[TBL] [Abstract][Full Text] [Related]
25. Prognostic importance of thymidine kinase in colorectal and breast cancer.
Svobodova S; Topolcan O; Holubec L; Treska V; Sutnar A; Rupert K; Kormunda S; Rousarova M; Finek J
Anticancer Res; 2007; 27(4A):1907-9. PubMed ID: 17649793
[TBL] [Abstract][Full Text] [Related]
26. [Biochemical markers of multiple myeloma].
Izumi T; Sasaki R
Nihon Rinsho; 1995 Mar; 53(3):622-6. PubMed ID: 7699895
[TBL] [Abstract][Full Text] [Related]
27. Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters.
Masaki Y; Itoh K; Sawaki T; Karasawa H; Kawanami T; Fukushima T; Kawabata H; Wano Y; Hirose Y; Suzuki T; Sugai S; Umehara H
Clin Chim Acta; 2006 Sep; 371(1-2):148-51. PubMed ID: 16643879
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.
Diem H; Fateh-Moghadam A; Lamerz R
Clin Investig; 1993 Nov; 71(11):918-23. PubMed ID: 8312685
[TBL] [Abstract][Full Text] [Related]
29. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
[TBL] [Abstract][Full Text] [Related]
30. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
[TBL] [Abstract][Full Text] [Related]
32. Serum free light chains for monitoring multiple myeloma.
Tate J; Mollee P; Gill D
Br J Haematol; 2005 Feb; 128(3):405-6; author reply 406-7. PubMed ID: 15667546
[No Abstract] [Full Text] [Related]
33. [Testis cancer markers. Clinical use].
Salesi N; Di Cocco B; Alghisi F; Calabretta F; Bossone G
Minerva Med; 2002 Oct; 93(5):365-9. PubMed ID: 12410169
[TBL] [Abstract][Full Text] [Related]
34. Salivary amylase-producing multiple myeloma: case report and review of the current literature.
Sosnoff DR; Friend RB; Berkovic M; Rasansky RJ; Hoffman SM
J Clin Oncol; 2013 Jul; 31(19):e309-11. PubMed ID: 23690421
[No Abstract] [Full Text] [Related]
35. [Analysis of abnormal enzyme activities--with special reference to LD].
Fujita K
Rinsho Byori; 1999 Feb; Suppl 109():140-9. PubMed ID: 10198589
[No Abstract] [Full Text] [Related]
36. Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia.
Dalley CD; Lister TA; Cavenagh JD; Rohatiner AZ
Br J Cancer; 2001 Jan; 84(1):147. PubMed ID: 11139330
[No Abstract] [Full Text] [Related]
37. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
38. [Lactic dehydrogenase as a prognostic factor in the development of pulmonary metastatic disease in patients with osteosarcoma].
López-Aguilar E; Rivera-Márquez H; Cerecedo-Díaz F; Peniche-Villalpando L
Gac Med Mex; 1996; 132(4):363-6. PubMed ID: 8964378
[TBL] [Abstract][Full Text] [Related]
39. Chronobiological aspects of phosphohexoseisomerase in monitoring multiple myeloma.
Neri B; Becucci A; Ciapini A; Comparini T; Guidi G; Guidi S
Oncology; 1983; 40(5):332-5. PubMed ID: 6621995
[TBL] [Abstract][Full Text] [Related]
40. Clinical impact of discordance in serum albumin measurements on myeloma international staging system.
Kapoor P; Snozek CL; Colby C; Larson DR; Katzmann JA; Rajkumar SV; Greipp PR
J Clin Oncol; 2008 Aug; 26(24):4051-2. PubMed ID: 18711203
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
